Finemedix - Public Comps and Valuation Multiples

Finemedix Overview

About Finemedix

Finemedix Co Ltd is engaged in manufacturing of other medical and surgical equipment and orthopedic appliances. The company is engaged in production of endoscopic surgical instruments and domestically produced functionally endoscopic incisions, snares, etc. The company is supplying its products to several university hospitals, large hospitals, and clinics in Korea, and are continuously planning and developing products that actively reflect the ideas of developed domestic medical staff and voices from the field. In addition, the company is preparing for overseas exports by obtaining CE and FDA certifications and is emerging as a specialized medical device company.

Founded

2009

HQ

Employees

n/a

Website

finemedix.com

Sectors

Medical Devices
HealthTech

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$26.3M

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Finemedix Financials

Finemedix has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Finemedix achieved revenue of $6.8M and an EBITDA of $0.6M.

Finemedix expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Finemedix valuation multiples based on analyst estimates

Finemedix P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$6.9M	$6.8M	XXX	XXX	XXX
Gross Profit	$3.0M	$3.8M	XXX	XXX	XXX
Gross Margin	43%	57%	XXX	XXX	XXX
EBITDA	$1.6M	$0.6M	XXX	XXX	XXX
EBITDA Margin	23%	9%	XXX	XXX	XXX
Net Profit	$0.2M	$0.8M	XXX	XXX	XXX
Net Margin	2%	12%	XXX	XXX	XXX
Net Debt	$2.5M	$1.4M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Finemedix Stock Performance

As of April 15, 2025, Finemedix's stock price is KRW 8290 (or $6).

Finemedix has current market cap of KRW 45.0B (or $30.7M), and EV of KRW 38.5B (or $26.3M).

See Finemedix trading valuation data

Finemedix Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$26.3M	$30.7M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Finemedix Valuation Multiples

As of April 15, 2025, Finemedix has market cap of $30.7M and EV of $26.3M.

Finemedix's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Finemedix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for Finemedix and 10K+ public comps

Finemedix Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$26.3M	XXX	XXX	XXX
EV/Revenue	3.9x	XXX	XXX	XXX
EV/EBITDA	42.5x	XXX	XXX	XXX
P/E	-1863.9x	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	-90.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Finemedix Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Finemedix Valuation Multiples

Finemedix's NTM/LTM revenue growth is n/a

Finemedix's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Finemedix's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate Finemedix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for Finemedix and other 10K+ public comps

Finemedix Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	-2%	XXX	XXX	XXX	XXX
EBITDA Margin	9%	XXX	XXX	XXX	XXX
EBITDA Growth	-61%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	n/a	XXX	XXX	XXX	XXX
Revenue per Employee	n/a	XXX	XXX	XXX	XXX
Opex per Employee	n/a	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	9%	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	8%	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	6%	XXX	XXX	XXX	XXX
Opex to Revenue	58%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry